EGFR and non-small cell lung carcinoma: Numerous studies showed that in patients with advanced NSCLC carrying EGFR mutations, treatment with epidermal growth factor receptor –tyrosine kinase inhibitors (EGFR-TKIs) improved chances of survival [2–6].